- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT05245279
Placental Perfusion in the Entire Placenta and With Sonobiopsy by Ultrasound
16 febbraio 2022 aggiornato da: Andrea Suranyi, Szeged University
Correlation Between the Placental Perfusion Measured in the Entire Placenta and With Sonobiopsy
In this study is tested the validity of placental vascular indices obtained from placenta ultrasonographic sphere biopsy and entire placenta investigation.
Panoramica dello studio
Stato
Completato
Condizioni
Descrizione dettagliata
Although, to this date, there have been a number of human placental studies that concerned the evaluation of placental 3 dimensional power Doppler vascularization with the use of VOCAL technique, but there was no one in which placental vasculature has been compared between the sonobiopsy and whole placental volume.
Tipo di studio
Interventistico
Iscrizione (Effettivo)
150
Fase
- Non applicabile
Contatti e Sedi
Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.
Luoghi di studio
-
-
-
Szeged, Ungheria, 6720
- Universitiy of Szeged
-
-
Criteri di partecipazione
I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.
Criteri di ammissibilità
Età idonea allo studio
Da 18 anni a 45 anni (Adulto)
Accetta volontari sani
No
Sessi ammissibili allo studio
Femmina
Descrizione
Exclusion criteria:
- multiple pregnancy,
- abnormal (> 3mm) nuchal translucency from 11+0 to 13+6 weeks of gestation,
- the fetal or neonatal structural or chromosomal anomaly,
- inadequate localization of the placenta (placenta praevia),
- self-reported drugs, alcohol, caffeine or nicotine abuse,
- exposed to circulatory medication (oxerutins, calcium dobesilate)
- or not signing the consent form.
- If the mother suffer from er systemic disease (e.g. diabetes, autoimmune disease, vasculitis, haemophilia, thrombophilia, HIV infection, etc)
Inclusion clriteria:
- single pregnancy
- healthy pregnant women
- no anatomical alteration of fetus
- no genetical abnormality of fetus
Piano di studio
Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Diagnostico
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Normal placenta-entitle
The 3-DPD indices was measured in the entire placenta volume.
|
Images that contributed to the determination of placental volume and 3-DPD indices were obtained at the time of visit.
All 3-D scans ultrasound measurements were performed by a Voluson 730 Expert ultrasound machine equipped with a multifrequency probe (2-5 MHz) to acquire images.
Each sample was examined using 3-D rendering mode, in which the colour and gray value information was processed and combined to supply 3-D image.
For laterally located placentas, the investigator positioned the transducer on a slight lateral inclination to obtain proper images.
Power Doppler window was placed over the placenta to map the vascular tree from basal to chorionic plates.
The 3-D static volume box was placed over the entire placenta volume.
The sweep angle was set at maximum 70°.
Each image was recovered from the disk in succession for processing.
During gestation, the investigator recorded one sample from each patient.
The two-dimensional (2-D) transabdominal conventional study provided data about fetal position, biometry, body movements and fetal heart rate as well as placental localization.
The factorial default setting 'Obstetrics' was applied in 2-D mode.
|
|
Sperimentale: Normal placenta-sonobyopsy
The 3-DPD indices was measured at cord insertion in placenta by sonobiopsy
|
Images that contributed to the determination of placental volume and 3-DPD indices were obtained at the time of visit.
All 3-D scans ultrasound measurements were performed by a Voluson 730 Expert ultrasound machine equipped with a multifrequency probe (2-5 MHz) to acquire images.
Each sample was examined using 3-D rendering mode, in which the colour and gray value information was processed and combined to supply 3-D image.
For laterally located placentas, the investigator positioned the transducer on a slight lateral inclination to obtain proper images.
Power Doppler window was placed over the placenta to map the vascular tree from basal to chorionic plates.
The 3-D static volume box was placed over the entire placenta volume.
The sweep angle was set at maximum 70°.
Each image was recovered from the disk in succession for processing.
During gestation, the investigator recorded one sample from each patient.
The two-dimensional (2-D) transabdominal conventional study provided data about fetal position, biometry, body movements and fetal heart rate as well as placental localization.
The factorial default setting 'Obstetrics' was applied in 2-D mode.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Maternal characteristics (BMI)
Lasso di tempo: through study completion, 2 years
|
The pre-pregnancy body mass index (BMI) registered at the initial visit during prenatal care was calculated as the body weight (kg) per height (m2).
|
through study completion, 2 years
|
|
Neonatal outcome 1; based on gestational age
Lasso di tempo: during first day of life
|
The participants were recorded by gestational age et birth
|
during first day of life
|
|
Neonatal outcome 2, based on maturation of neonates
Lasso di tempo: during first day of life
|
Neonates were investigatied by maturation ( gestational age before 36+6 week) (prematurity
|
during first day of life
|
|
Neonatal outcome 3, (birth weight of newborns)
Lasso di tempo: during first day of life
|
Neonates birth weight calculation (gram)
|
during first day of life
|
|
Neonatal outcome 4; Apgar score
Lasso di tempo: during first day of life
|
Neonates poor adaptation status (Apgar score (<7) at 5 minutes)
|
during first day of life
|
|
Neonatal outcome 5, (umbilical cord pH)
Lasso di tempo: during first day of life
|
Neonates poor adaptation status (umbilical cord pH <7.2)
|
during first day of life
|
|
Neonatal outcome 6; delivery complication
Lasso di tempo: during first day of life
|
Delivery complication ( cesarean section due to fetal distress)
|
during first day of life
|
|
Neonatal outcome 7, necessary of intensive care unit
Lasso di tempo: during first week of life
|
Neonates transfer to neonatal intensive care unit (NICU)
|
during first week of life
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
2D ultrasound investigaiotn of gestation (fetal biometry, placentation)
Lasso di tempo: during prenatal care till the labour
|
Routine ultrasound examination, based on Guideline of Hungarian Obstetrics and gynecologists (fetal biometry: biparietal diameter, head circumference, abdominal circumference, femur length; investigation of the placenta, place of placentation, Grannum staging)
|
during prenatal care till the labour
|
Collaboratori e investigatori
Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.
Sponsor
Investigatori
- Cattedra di studio: Tibor Wittman, Professor, ALBERT SZENT-GYÖRGYI CLINICAL CENTER. REGIONAL SCIENTIFIC AND RESEARCH COMMITTEE FOR HUMAN BIOLOGICAL SCIENCE.
Pubblicazioni e link utili
La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.
Pubblicazioni generali
- Odibo AO, Zhong Y, Longtine M, Tuuli M, Odibo L, Cahill AG, Macones GA, Nelson DM. First-trimester serum analytes, biophysical tests and the association with pathological morphometry in the placenta of pregnancies with preeclampsia and fetal growth restriction. Placenta. 2011 Apr;32(4):333-8. doi: 10.1016/j.placenta.2011.01.016. Epub 2011 Feb 13.
- Molnar A, Suranyi A, Jako M, Nyari T, Nemeth G. [Examination of placental three-dimensional power Doppler indices and perinatal outcome in pregnancies complicated by intrauterine growth restriction]. Orv Hetil. 2017 Jul;158(26):1008-1013. doi: 10.1556/650.2017.30784. Hungarian.
- Kozinszky Z, Suranyi A, Peics H, Molnar A, Pal A. Placental Volumetry by 2-D Sonography with a New Mathematical Formula: Prospective Study on the Shell of a Spherical Sector Model. Ultrasound Med Biol. 2015 Aug;41(8):2252-8. doi: 10.1016/j.ultrasmedbio.2015.04.005. Epub 2015 May 7.
- Collins SL, Stevenson GN, Noble JA, Impey L. Rapid calculation of standardized placental volume at 11 to 13 weeks and the prediction of small for gestational age babies. Ultrasound Med Biol. 2013 Feb;39(2):253-60. doi: 10.1016/j.ultrasmedbio.2012.09.003. Epub 2012 Dec 4.
- Moran M, McAuliffe FM. Imaging and assessment of placental function. J Clin Ultrasound. 2011 Sep;39(7):390-8. doi: 10.1002/jcu.20846. Epub 2011 Jun 8.
- Plasencia W, Akolekar R, Dagklis T, Veduta A, Nicolaides KH. Placental volume at 11-13 weeks' gestation in the prediction of birth weight percentile. Fetal Diagn Ther. 2011;30(1):23-8. doi: 10.1159/000324318. Epub 2011 Jun 23.
- Merce LT, Barco MJ, Bau S. Reproducibility of the study of placental vascularization by three-dimensional power Doppler. J Perinat Med. 2004;32(3):228-33. doi: 10.1515/JPM.2004.043.
Collegamenti utili
- First trimester placental and myometrial blood perfusion measured by 3D power Doppler in normal and unfavourable outcome pregnancies
- Matijevic R, Kurjak A. The assessment of placental blood vessels by three-dimensional power Doppler ultrasound
- Odibo AO, Goetzinger KR, Huster KM, Christiansen JK, Odibo L, Tuuli MG. Placental volume and vascular flow assessed by 3D power Doppler and adverse pregnancy outcomes
- Pairleitner H, Steiner H, Hasenoehrl G, Staudach A. Three-dimensional power Doppler sonography: imaging and quantifying blood flow and vascularization
- Tuuli MG, Houser M, Odibo L, Huster K, Macones GA, Odibo AO. Validation of placental vascular sonobiopsy for obtaining representative placental vascular indices by three-dimensional power Doppler ultrasonography
- Evaluation of placental vascularization by three-dimensional ultrasound examination in second and third trimester of pregnancies complicated by chronic hypertension, gestational hypertension or pre-eclampsia
- Surányi A, Kozinszky Z, Molnár A, Németh G. Placental volume relative to fetal weight estimated by sonography in diabetic pregnancies
- Demers S, Boutin A, Dembickaja R, Campanero M, Nicolaides K. Factors Associated with Placental Vascularization Measured by 3D Power Doppler Ultrasonographic Sphere Biopsy between 11 and 14 Weeks of Gestation
- Demers S, Girard M, Roberge S, Tetu A, Giguere Y, Forest J-C, et al. First-Trimester Placental and Myometrial Blood Perfusion Measured by Three-Dimensional Power Doppler in Preeclampsia
Studiare le date dei record
Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.
Studia le date principali
Inizio studio (Effettivo)
1 gennaio 2018
Completamento primario (Effettivo)
1 gennaio 2020
Completamento dello studio (Effettivo)
1 gennaio 2021
Date di iscrizione allo studio
Primo inviato
1 dicembre 2021
Primo inviato che soddisfa i criteri di controllo qualità
16 febbraio 2022
Primo Inserito (Effettivo)
17 febbraio 2022
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
17 febbraio 2022
Ultimo aggiornamento inviato che soddisfa i criteri QC
16 febbraio 2022
Ultimo verificato
1 febbraio 2022
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 120/2015
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
No
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
No
prodotto fabbricato ed esportato dagli Stati Uniti
No
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .